Publications-abstracts

NovellusDx is proud to support the clinical and academic communities. If you would like to collaborate on your research, please contact us directly.

Novel Platform to Profile Variants of Uncertain Significant (VUS) with Preliminary Retrospective Clinical Validation in Non-Small Cell Lung Cancer (NSCLC)

AACR Annual Meeting 2017

Benjamin Miron1, Gabi Tarcic1, Oded Edelheit1, Nitza Burck1, Michael Vidne1, Laila Roisman2, Nir Peled2

1. NovellusDx, Jerusalem, IL,

2. Davidoff Cancer Center, Petah Tikvah, IL

Sub-Clonal Therapy by two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-mutated Lung Cancer

Journal of Thoracic Oncology, 2017

Nir Peled, MD, PhD1, 2, Laila C. Roisman, PhD1, Benjamin Miron, MD3, Raphael Pfeffer, MD4, Richard B. Lanman, MD5, Maya Ilouse, PhD1, Addie Dvir6, Lior Soussan-Gutman6, Fabrice Barlesi, MD, PhD7, Gabi Tarcic, PhD3, Oded Edelheit, PhD3, David Gandara, MD8, Yehiel Elkabetz, PhD9

  1. Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel
  2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  3. NovellusDx, Jerusalem, Israel
  4. Assuta Medical Center, Tel Aviv, Israel
  5. Guardant Health, Inc., Redwood City, CA, USA
  6. Oncotest, Teva Pharmaceutical Industries Ltd., Shoam, Israel
  7. Aix Marseille University; Assistance Publique Hôpitaux de Marseille. Multidisciplinary Oncology & Therapeutic Innovations Dept. Marseille, France
  8. University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
  9. Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel

Phase 1B Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation

Cancer Discovery, 2016

David S. Hong1,*, Van K. Morris2, Badi El Osta3, Alexey V. Sorokin2, Filip Janku1, Siqing Fu1, Michael J. Overman2, Sarina Piha-Paul1, Vivek Subbiah1, Bryan Kee2, Apostolia Tsimberidou1, David Fogelman2, Jorge Bellido1, Imad Shureiqi2, Helen Huang1, Johnique Atkins1, Gabi Tarcic4, Nicolas Sommer5, Richard Lanman6, Funda Meric-Bernstam1 and Scott Kopetz2

  1. Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
  2. Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
  3. Medical Oncology, Emory University School of Medicine
  4. NovellusDX
  5. Genentech
  6. Guardant Health

Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance detected in patients enrolled in the SHIVA trial

EORTC-NCI-AACR, 2016

G. Tarcic1, M. Kamal2, O. Edelheit1, Z. Barbash1, M. Vidne1, B. Miron1, C. Callens2, N. Servant2, I. Bieche2, C. LeTourneau2

  1. NovellusDx, Jerusalem, Israel
  2. Institut Curie, Paris, France

Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025) – interim results

ESMO Annual Meeting, 2016

B. Miron1, N. Peled2, G. Tarcic1, Z. Barbash1, O. Edelheit1, M. Vidne1, M.R. Kramer3

  1. R&D, NovellusDx, Jerusalem, Israel,
  2. Thoracic Cancer Unit, Davidoff Cancer Center, Petach Tiqwa, Israel,
  3. Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel

Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD)

ESMO Annual Meeting, 2016

G. Tarcic1, C.M. Walko2, H.L. McLeod2, J.K. Hicks2, Z. Barbash1, O. Edelheit1, B. Miron1, M. Vidne1, E. Padron2

  1. NovellusDx, Jerusalem, Israel
  2. Malignant Hematology, H. Lee Moffitt Cancer Center University of South Florida, Tampa, FL, USA

Functional characterization of mutations and their interaction using the novel functional annotation for cancer treatment (FACT) platform

ESMO Annual Meeting, 2016

B. Miron1, N. Peled2, Z. Barbash1, O. Edelheit1, M. Vidne1, R. Sharivkin1 and G. Tarcic1

  1. NovellusDx, Jerusalem, Israel
  2. Thoracic Cancer Unit, Davidoff Cancer Center, Petach Tiqwa, Israel

Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram).

ASCO Annual Meeting, 2016

R. J. Sullivan1, Z. Barbash2, O. Edelheit2, M. Vidne2, J. A. Sosman3, K. Flaherty1, M. A. Davies4, D. B. Johnson3, G. Tarcic2

  1. Massachusetts General Hospital, Boston, MA
  2. NovellusDx, Jerusalem, Israel; Novellusdx, Jerusalem, Israel
  3. Vanderbilt-Ingram Cancer Center, Nashville, TN
  4. Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston, MA
  5. The University of Texas MD Anderson Cancer Center, Houston, TX
  6. Vanderbilt University, Nashville, TN

Functional characterization of VUS mutations found in patients’ cellfree circulating tumor DNA (ctDNA) using Precision Cancer Analysis System (PCAS)

ASCO Annual Meeting, 2016

G. Tarcic1, D. A. Simon2, M. Jacobstein2, R. B. Lanman2, M. Vidne1, Z. Barbash1, O. Edelheit1, A. Talasaz2;

  1. NovellusDx, Jerusalem, Israel
  2. Guardant Health, Redwood City, CA

Identification of the functional significance of mutations using the novel Precision Cancer Analysis System.

ASCO Annual Meeting, 2015

N. Peled1, Z. Barbash2, N. Barabash-Katzir2, H. Nevo2, M. Vidne2, M. Adamek3, M. R. Kramer4, N. Goncharenko5, Y. Fellig6, K. Meir6, G. Tarcic2;

  1. Davidoff Cancer Center, Petach Tiqwa, Israel
  2. NovellusDx, Jerusalem, Israel
  3. Medical University of Silesia, Zabrze, Poland
  4. Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
  5. IBBL (Integrated BioBank of Luxembourg), Luxembourg, Luxembourg
  6. Hadassah-Hebrew-University-Medical-Cente, Jerusalem, Israel